‘Orphan drugs’ in cardiology: nadolol and quinidine
Authors:
- Giuseppe InamaGIGiuseppe Inama
- Ornella DurinODOrnella Durin
- Claudio PedrinazziCPClaudio Pedrinazzi
- Massimo Zoni BerissoMBMassimo Zoni Berisso
- Francesco FurlanelloFFFrancesco Furlanello
- 1 February 2010
- journal article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 11 (2) , 143-144
Abstract
The recent withdrawal from the market of nadolol (Corgard; Bristol-Myers Squibb, Sermoneta, Italy) and quinidine polygalacturonate (Ritmocor; Malesci, Bagno A Ripoli, Italy) has been causing clinical problems to many cardiologists and patients, frequently leading to discontinuance of an effective and well-tolerated pharmacological treatment. Nadolol is useful in the treatment of severe and refractory arrhythmias, particularly in some genetically determined ion-channel diseases, such as long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia.Quinidine is still used in refractory atrial fibrillation recurrences. Recent studies have demonstrated the clinical efficacy of quinidine in the treatment of rare genetically determined ion-channel diseases at high risk of sudden death, such as Brugada syndrome and short-QT syndrome.We hope that scientific societies can influence healthcare and pharmaceutical institutions, in order to restore the availability of two cardiovascular drugs that are extremely important in the care of arrhythmic patients.Keywords
This publication has 8 references indexed in Scilit:
- Quinidine RevisitedThe American Journal of Medicine, 2009
- Empiric quinidine therapy for asymptomatic Brugada syndrome: Time for a prospective registryHeart Rhythm, 2009
- Quinidine: a valuable medication joins the list of 'endangered species'EP Europace, 2007
- Efficacy of beta-blocking agents in reducing the number of shocks in patients implanted with first-generation automatic defibrillatorsEuropean Heart Journal, 1992
- Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.Circulation, 1990
- Antiarrhythmic effects of beta-adrenergic blocking agents in benign or potentially lethal ventricular arrhythmiasThe American Journal of Cardiology, 1987
- Anti-arrhythmic action of nadolol, a β-adrenergic receptor blocking agentEuropean Journal of Pharmacology, 1976